LCTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LCTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lineage Cell Therapeutics's current ratio for the quarter that ended in Dec. 2023 was 2.14.
Lineage Cell Therapeutics has a current ratio of 2.14. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lineage Cell Therapeutics's Current Ratio or its related term are showing as below:
During the past 13 years, Lineage Cell Therapeutics's highest Current Ratio was 8.86. The lowest was 2.14. And the median was 4.19.
The historical data trend for Lineage Cell Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Current Ratio | Get a 7-Day Free Trial | 8.86 | 5.66 | 2.37 | 3.16 | 2.14 |
Lineage Cell Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Current Ratio | Get a 7-Day Free Trial | 3.16 | 2.88 | 3.02 | 2.74 | 2.14 |
For the Biotechnology subindustry, Lineage Cell Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Current Ratio falls into.
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
Lineage Cell Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Current Ratio (A: Dec. 2023 ) | = | Total Current Assets (A: Dec. 2023 ) | / | Total Current Liabilities (A: Dec. 2023 ) |
= | 38.441 | / | 17.96 | |
= | 2.14 |
Lineage Cell Therapeutics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as
Current Ratio (Q: Dec. 2023 ) | = | Total Current Assets (Q: Dec. 2023 ) | / | Total Current Liabilities (Q: Dec. 2023 ) |
= | 38.441 | / | 17.96 | |
= | 2.14 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics (AMEX:LCTX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Anula Jayasuriya | director | 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022 |
Jill Ann Howe | officer: Chief Financial Officer | C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121 |
Dipti Amin | director | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Brian M Culley | director, officer: President and CEO | 6725 MESA RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121 |
Broadwood Partners Lp | 10 percent owner | BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019 |
Michael H. Mulroy | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
Gary S. Hogge | officer: SVP,Clinical & Medical Affairs | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Samuel George A. Iii | officer: General Counsel/Secretary | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Angus C. Russell | director | C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Kevin Leon Cook | officer: Chief Financial Officer | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Alexandra Hernandez | officer: Sr Director Finance/Controller | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Brandi Roberts | officer: CFO & SVP, Finance | 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130 |
Chase C. Leavitt | officer: General Counsel/Secretary | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Edward Wirth | officer: Chief Medical Officer | C/O INVIVO THERAPEUTICS HOLDING CORP., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Don M Bailey | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92607 |
From GuruFocus
By PRNewswire PRNewswire • 10-15-2020
By gurujk gurujk • 06-27-2011
By PRNewswire PRNewswire • 06-24-2022
By PRNewswire PRNewswire • 07-04-2022
By PRNewswire PRNewswire • 07-04-2022
By PRNewswire PRNewswire • 06-24-2022
By Marketwired Marketwired • 02-26-2019
By PRNewswire PRNewswire • 06-14-2022
By PRNewswire PRNewswire • 07-14-2022
By PRNewswire PRNewswire • 06-01-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.